Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Tivozanib Showcases Superiority in Relapsed/Refractory RCC
Tivozanib demonstrated a significant improvement in progression-free survival when compared with sorafenib, with similar overall survival, in patients with highly relapsed or refractory metastatic renal cell carcinoma.
Novel Anti-TIGIT Agent Tiragolumab Plus Atezolizumab Impresses in NSCLC
May 29th 2020Patients with chemotherapy-naïve, locally advanced or metastatic non–small cell lung cancer who were treated in the phase 2 CITYSCAPE trial with tiragolumab, an inhibitor of the immunomodulatory receptor TIGIT, plus and anti–PD-L1 agent demonstrated better efficacy versus single-agent checkpoint inhibitor therapy alone.
Carfilzomib Triplet Does Not Improve Outcomes Versus Standard of Care in Newly Diagnosed Myeloma
May 29th 2020The combination of next-generation proteasome inhibitor carfilzomib, lenalidomide, and dexamethasone did not show a superiority in progression-free survival in patients with newly diagnosed multiple myeloma when compared with the current standard of care triplet of bortezomib, lenalidomide and dexamethasone.
Locoregional Therapy Does Not Improve OS in Advanced Breast Cancer
Data from the long-awaited ECOG-ACRIN E2108 trial showed that surgery and radiation to the tumor does not extend overall survival compared with systemic treatment alone in women with stage IV breast cancer.
Using a Multinational Pediatric Cancer Registry Helps to Improve PFS in High-Risk Patients
May 29th 2020The use of real-time comprehensive profiling provides valuable diagnostic information and identifies potential therapeutic targets in adults with malignancies, but this process remains widely underutilized for pediatric patients and represents a significant unmet need.
Avelumab Controls hCG Levels Lead to Remissions in Gestational Trophoblastic Tumors
May 29th 2020Gestational trophoblastic tumors (GTTs) that resist chemotherapy can be treated with frontline avelumab, making avelumab the first immunotherapy to show efficacy in treating patients with GTT, according to findings from a cohort of the ongoing phase 2 TROPHIMMUN trial.
Avelumab Extends Survival as Frontline Maintenance in Urothelial Carcinoma
May 29th 2020Adding avelumab to best supportive care improved the median overall survival by over 7 months in patients with locally advanced or metastatic urothelial carcinoma, according to findings from the phase 3 JAVELIN Bladder 100 study.
Pembrolizumab Doubles PFS in Newly Diagnosed MSI-H/dMMR mCRC
May 29th 2020Pembrolizumab doubled progression-free survival compared with chemotherapy in patients with newly diagnosed microsatellite instability–high/mismatch repair deficient metastatic colorectal cancer, according to findings from an interim analysis of the phase 3 KEYNOTE-177 trial.
Active Cancer Strongly Associated With Increased COVID-19 Mortality
An analysis of data collected in the COVID-19 and Cancer Consortium registry showed that patients with progressive cancer were 5.2-times more likely to die within 30 days of being diagnosed with novel coronavirus 19 compared with patients in remission or with no evidence of disease.
Addition of Veliparib to Carboplatin-Paclitaxel Increases PFS in HR+ Breast Cancer, TNBC
May 27th 2020The PARP inhibitor veliparib increased progression-free survival in women with hormone receptor-positive breast cancer and triple-negative breast cancer who harbored a germline BRCA1/2 mutation when co-administered with carboplatin and paclitaxel, according to findings from the phase 3 BROCADE3 trial (NCT02163694).
Top Priorities Outlined in Next Decade of Breast Cancer Research
May 26th 2020Developing diagnostics to identify the molecular drivers of breast cancer and model the mechanisms of disease progression will be a key priority of the investigative efforts aimed at improving patient outcomes in the field over the next decade.
LSZ102 Shows Encouraging Activity in Combination With Ribociclib, Alpelisib in ER+ Breast Cancer
May 26th 2020LSZ102 was found to be well tolerated and demonstrate clinical activity in combination with either ribociclib or alpelisib in patients with estrogen receptor–positive breast cancer who have progressed on endocrine therapy.
Mindful Adaptation of Breast Cancer Treatment Necessary Amid COVID-19 Crisis
Although little evidence exists with regard to how to best treat patients with breast cancer during the COVID-19 pandemic, guidelines have been issued by organizations like ESMO to assist providers with making those decisions.
ASCO 2020: Oncology Experts Select Vital Studies Ahead of Virtual Meeting
May 21st 2020We spoke with leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their specialties.
ASCO 2020: Top KOLs Select Vital Studies Ahead of Virtual Meeting
May 21st 2020Ahead of the 2020 ASCO Virtual Scientific Program, we spoke with a handful of leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their respective specialties.
Regardless of Timing, Smoking Cessation Before Lung Cancer Diagnosis Shows Survival Benefit
May 14th 2020People who quit smoking at any time, even up to 2 years before a lung cancer diagnosis, have increased chances of survival after their diagnosis, according to data during a 2020 ASCO Virtual Scientific Program press briefing.
.jpg?fit=crop&auto=format)
